Tiziana Life Sciences (TLSA)

• Market cap: $143M
• 1 day: -2.61%
• 5 days: 10.89%
• 1 month: 9.8%
• 3 months: -17.04%
• 6 months: -20%
• Year to date: -30%
• 1 year: -40.74%
• 5 years: -30.86%
• 10 years: -32.93%
• Sector: Healthcare
• Industry: Biotechnology

About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Employees: 10